Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Temozolomide 61Radiotherapy 25Bevacizumab 21Magnetic Resonance Spectroscopy 20Irinotecan 18Filgrastim 15Carboplatin 15Carmustine 11Surgical Procedures, Operative 10Etoposide 9antineoplaston AS 2-1 8antineoplaston A10 8Specimen Handling 8sargramostim 7Radiation 7Peripheral Blood Stem Cell Transplantation 7Everolimus 7Biopsy 7Vincristine 6Radiotherapy, Intensity-Modulated 6Procarbazine 6O(6)-benzylguanine 6Erlotinib Hydrochloride 6Topotecan 5Melphalan 5Magnetic Resonance Imaging 5Lomustine 5Genetic Therapy 5Cyclophosphamide 5Aminolevulinic Acid 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Astrocytoma × regadenoson × Clear all
NCT03971734 2023-10-06

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
7 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡